Publications

Leask J, Braunack-Mayer A, Kerridge I. Consent and public engagement in an era of expanded childhood immunisation. Journal of Paediatrics and Child Health 2011;47:603-7. [Full text]

Garland SM, Brotherton JM, Condon JR, McIntyre PB, Stevens MP, Smith DW, Tabrizi SN. Human papillomavirus prevalence among Indigenous and non-Indigenous Australian women prior to a national HPV vaccination program. BMC Medicine 2011;9:104. [Full text]

Ridda I, Seale H, Katelaris AL, Heywood AE, Tan TC, MacIntyre CR, Dwyer DE. Pneumococcal colonisation following influenza infection [letter] . Vaccine 2011;29:6444-5.. [Full text]

Quinn HE, McIntyre PB. The impact of adolescent pertussis immunization, 2004–2009: lessons from Australia. Bulletin of the World Health Organization 2011;89:666-74. [Full text]

Christie D, Viner RM, Knox K, Coen PG, Wang H, El Bashir H, Legood R, Patel BC, Booy R. Long-term outcomes of pneumococcal meningitis in childhood and adolescence. European Journal of Pediatrics 2011;170:997-1006 . [Abstract]

Eizenberg P, Booy R, Naser N, Mason G, Stamboulian D, Weber F. Acceptance of Intanza® 9 µg intradermal influenza vaccine in routine clinical practice in Australia and Argentina. Advances in Therapy 2011;28:640-9. [Full text]

Yin JK, Wang H, Skinner SR, Salkeld G, Booy R. Assessing seasonal vaccine-related cross-protection from 2009 pandemic H1N1 influenza through teacher absenteeism [letter] . Australian and New Zealand Journal of Public Health 2011;35:393-4. [Full text]

Isaacs D, Kilham HA, Alexander S, Wood N, Buckmaster A, Royle J. Ethical issues in preventing mother-to-child transmission of hepatitis B by immunisation. Vaccine 2011;29:6159-62 . [Full text]

Hull B, Dey A, Mahajan D, Menzies R, McIntyre PB. Immunisation coverage annual report, 2009. Communicable Diseases Intelligence 2011;35:132-48. [Full text]

Van Damme P, McIntyre P, Grimprel E, Kuriyakose S, Jacquet JM, Hardt K, Messier M, Van Der Meeren O. Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix®) in adults 55 years of age and over: a sub-analysis of four trials. Vaccine 2011;29:5932-9. [Full text]